NR1I3 and fatty liver disease: To confirm whether the improvement of hepatic steatosis after pioglitazone in CAR−/− mice resulted from a higher concentration of pioglitazone or was related to the absence of CAR itself, we made similar serum pioglitazone concentrations for both CAR+/+ and CAR−/− mice.